𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines

✍ Scribed by Jens Wagenblast; Markus Hambek; Mehran Baghi; Wolfgang Gstöttner; Klaus Strebhardt; Hanns Ackermann; Rainald Knecht

Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
460 KB
Volume
134
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P53 mutation correlates with cisplatin s
P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines
✍ Carol R. Bradford; Shaobo Zhu; Haruko Ogawa; Tetsuya Ogawa; Matthew Ubell; Ajita 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 2 views

## Background: A critical factor for successful organ preservation treatment in head and neck cancer may be selecting tumors that respond to chemotherapy and radiation. previous results in patients indicated that tumors that overexpressed p53 were more sensitive to chemotherapy than those that did

Hyperphosphorylation of replication prot
Hyperphosphorylation of replication protein A in cisplatin-resistant and -sensitive head and neck squamous cell carcinoma cell lines
✍ Karoline C. Manthey; Jason G. Glanzer; Diana D. Dimitrova; Greg G. Oakley 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 3 views

## Abstract ## Background Resistance to chemotherapy is a major limitation in the treatment of head and neck squamous cell carcinomas (HNSCCs), accounting for high mortality rates in patients. Here, we investigated the role of replication protein A (RPA) in cisplatin and etoposide resistance. ##

Butyrate response factor 1 enhances cisp
Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines
✍ Seung Koo Lee; Seong Bum Kim; Jong Soo Kim; Chang Hoon Moon; Myung Shin Han; Byu 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 456 KB 👁 1 views

Cisplatin is a widely used chemotherapeutic agent in head and neck squamous cell carcinoma (HNSCC). Resistance to cisplatin is a common feature of HNSCC. To identify genes that may regulate cisplatin sensitivity, we carried out a cDNA microarray analysis of gene expression in cisplatin-sensitive and

Combination chemotherapy with methotrexa
Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck
✍ M. Clavel; F. Cognetti; P. Dodion; J. Wildiers; R. Rosso; A. Rossi; B. Gignoux; 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 2 views

## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot